Fujirebio europe and centogene enter partnership to provide rapid and high-quality preventive sars-cov-2 antigen testing

Gent, belgium and cambridge, mass. and rostock, germany and berlin, nov. 09, 2020 (globe newswire) -- centogene n.v. (nasdaq: cntg), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and fujirebio europe announced today to have entered a partnership to leverage lumipulse® g technology for large-scale covid-19 antigen testing with further deployment in german airports.
CNTG Ratings Summary
CNTG Quant Ranking